5 slides from Telix Pharmaceuticals's fact sheet, June 2023
Slide 1: Changing the way we find and treat cancer and rare diseases
Changing the way we find and treat cancer and rare diseases Telix is an Australian-headquartered global healthcare business with international operations in Belgium, Japan, Switzerland, and the United States (U.S.). Telix’s targeted radiation imaging and therapy technologies have potential to transf
Slide 2: Our technology: a global leader in radiopharmaceuticals
Our technology A global leader in radiopharmaceuticals Telix is developing targeted radiation across the continuum from diagnosis Our point of difference: Theranostics for oncology and rare diseases and staging to treatment, both as stand-alone and “combination” therapies. harnessing the power Many
Slide 3: Telix Manufacturing Solutions (TMS)
Telix Manufacturing Solutions (TMS) The 2,800 sqm building includes a 965 sqm advanced radiopharmacy, with 9 clean rooms, Belgium has one of the highest concentrations of nuclear medicine equipment and specialists per 2 purification suites, 2 R&D laboratories, 2 quality control laboratories, 2 cyclo
Slide 4: Snapshot and Board of Directors
Snapshot Board of Directors ASX code Market capitalization Chairman H Kevin McCann AO TLX $3.7b Shares on issue 52 Week high/low MD/CEO $3.72 - $12.05 Dr Christian Behrenbruch $318.36m Date listed on ASX Market sector Non-Executive Directors 15 Nov 2017 Healthcare Dr Andreas Kluge All figures are in
Slide 5: Speaker bios and Telix contacts
Speaker bios Dr Christian Behrenbruch Raphaël Ortiz Managing Director and Group CEO EMEA CEO Dr Behrenbruch has over twenty years of healthcare Raphaël has more than 20 years of pharmaceutical entrepreneurship and executive leadership experience. industry experience in a variety of roles, including